公开(公告)号：US20240182422A1

公开(公告)日：2024-06-06

申请号：US18284253

申请日：2022-03-23

申请人： ABIVAX ,  CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE ,  UNIVERSITE DE MONTPELLIER ,  INSTITUT CURIE

发明人： Jérôme DENIS ,  Fabien DE BLASIO ,  Thierry BOYER ,  Charles GUERIN ,  Julien MICHAUX ,  Romain NAJMAN ,  Florence MAHUTEAU-BETZER

IPC分类号： C07D215/38

CPC分类号： C07D215/38

摘要： A method for preparing a compound of formula (I), a powder, and a pharmaceutical composition are disclosed. The method includes: (i) reacting a compound of formula (II) with a compound of formula (III), to form the hydrochloride salt of the compound of formula (I), and (ii) recovering the compound of formula (I) in the form of a free base through addition of a base. In step (i), the molar ratio of the compound of formula (II) to the compound of formula (III) is in a range of from 1.00:0.80 to 1.00:1.20, and no metal catalyst is present. A powder including the composition of formula (I) may be obtained by the method. The powder may have a particle size distribution with specific D50, D90 and/or D10 values. A pharmaceutical composition may include the powder and at least one pharmaceutically acceptable excipient.

公开(公告)号：US20210300871A1

公开(公告)日：2021-09-30

申请号：US17259483

申请日：2019-07-09

申请人： ABIVAX ,  CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE ,  UNIVERSITE DE MONTPELLIER ,  INSTITUT CURIE

发明人： Didier SCHERRER ,  Jamal TAZI ,  Florence MAHUTEAU-BETZER ,  Romain NAJMAN ,  Julien SANTO ,  Cécile APOLIT

IPC分类号： C07D213/38 ,  C07D401/12 ,  C07D241/12 ,  C07D213/75 ,  C07D239/42 ,  C07C233/65 ,  C07D213/81 ,  A61P31/12

摘要： A compound: wherein X1 represents an alkenylene group, a —NH—CO— group, a —CO—NH— group, Y1 represents an aryl group selected from pyridyl, pyrazinyl or pyrimidinyl, X2 represents —O—, —CO—NH—, —NH—CO—NH—, —OCH2—, —NH—CO—, a divalent 5-membered heteroaromatic ring comprising 1 to 4 heteroatoms or —SO2—NH—, and Y2 represents a hydrogen atom, a hydroxyl group, a morpholinyl group, a piperidinyl group, optionally substituted by a (C1-C4)alkyl group, a piperazinyl group, optionally substituted by a (C1-C4)alkyl group, or —CR1R2R3 or alternatively X2—Y2 represents —CONRcRd, wherein Rc and Rd form, together with the nitrogen atom a heterocyclic ring, optionally substituted by one or two (C1-C4)alkyl group, by a cyclopentyl group thus forming a spirocyclopentyl, or by a trifluoromethyl group, or any of its pharmaceutically acceptable salt, for use in the treatment and/or prevention of a RNA virus infection caused by a RNA virus belonging to group IV or V of the Baltimore classification.

公开(公告)号：US20240308964A1

公开(公告)日：2024-09-19

申请号：US18660578

申请日：2024-05-10

申请人： ABIVAX ,  CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE ,  UNIVERSITE DE MONTPELLIER ,  INSTITUT CURIE

发明人： Didier SCHERRER ,  Jamal TAZI ,  Florence MAHUTEAU-BETZER ,  Romain NAJMAN ,  Julien SANTO ,  Cécile APOLIT

IPC分类号： C07D215/38 ,  A61P31/14 ,  C07D401/12 ,  C07D405/12

CPC分类号： C07D215/38 ,  A61P31/14 ,  C07D401/12 ,  C07D405/12

摘要： A compound of formula (I) or any of its pharmaceutically acceptable salt for use in the treatment and/or prevention of a RNA virus infection, and a RNA virus infection from group IV or V of the Baltimore classification




wherein R3 represents a chlorine atom or a hydrogen atom, R represents a (C1-C4)alkyl group, a (C3-C6)cycloalkyl group, a halogen atom, a (C1-C5)alkoxy group, a —SO2—NRaRb group, a —SO3H group, a —OH group, a —O—SO2—ORc group or a —O—P(═O)—(ORc)(ORd) group, R1 represents (i) a CF3 group, (ii) a (C1-C10)alkyl group, (iii) a (C3-C6)cycloalkyl or a (C3-C6)heterocycloalkyl group or (iv) a phenyl group or a naphthyl group, and R2 represents a hydrogen atom, a (C1-C10)alkyl group, a (C3-C6)cycloalkyl or a (C3-C6)heterocycloalkyl group and further relates to new compounds, to pharmaceutical compositions containing them and to synthesis process for manufacturing them.

公开(公告)号：US20190022037A1

公开(公告)日：2019-01-24

申请号：US16153249

申请日：2018-10-05

申请人： CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE ,  INSTITUT CURIE ,  UNIVERSITE DE MONTPELLIER

发明人： Jamal TAZI ,  David GRIERSON ,  Florence MAHUTEAU-BETZER ,  Pierre ROUX

IPC分类号： A61K31/166 ,  A61K31/4725 ,  A61K31/417 ,  A61K31/4439 ,  A61K31/4409 ,  A61K31/4406 ,  A61K31/4192

摘要： Compounds and pharmaceutically acceptable salts thereof that may be used to treat a disease, for example, Duchenne muscular dystrophy, AIDS, and progeria. The compounds and pharmaceutically acceptable salts thereof may be part of a pharmaceutical composition including a pharmaceutically acceptable support.

公开(公告)号：US20220356175A1

公开(公告)日：2022-11-10

申请号：US17259370

申请日：2019-07-09

申请人： ABIVAX ,  CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE ,  UNIVERSITE DE MONTPELLIER ,  INSTITUT CURIE

发明人： Didier SCHERRER ,  Jamal TAZI ,  Florence MAHUTEAU-BETZER ,  Romain NAJMAN ,  Julien SANTO ,  Cécile APOLIT

IPC分类号： C07D413/12 ,  C07D239/16 ,  C07D405/12 ,  C07D239/22 ,  C07D403/12 ,  C07D401/12

摘要： A compound of formula (Ic) wherein X2 represents a —CO—NRk— group, wherein Rk represents a hydrogen atom or a methyl group, a —NH—CO—NH— group, a —OCH2— group, a —CH(OH)— group, a —NH—CO— group, a —O— group, a —O—(CH2)s—O—, a —CO— group, a —SO2— group, a divalent 5-membered heteroaromatic ring comprising 1, 2, 3 or 4 heteroatoms, —a NH—SO2— or a —SO2—NH— group; Y2 represents a hydrogen atom, a halogen atom, a hydroxyl group, a (C1-C4)alkoxy group, a a group, a group, a morpholinyl group, optionally substituted by a (C1-C4)alkyl group, a piperazinyl group, a piperidinyl group, or a —CR1R2R3 group, or any of its pharmaceutically acceptable salt.

公开(公告)号：US20210309611A1

公开(公告)日：2021-10-07

申请号：US17259364

申请日：2019-07-09

申请人： ABIVAX ,  CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE ,  UNIVERSITE DE MONTPELLIER ,  INSTITUT CURIE

发明人： Didier SCHERRER ,  Jamal TAZI ,  Florence MAHUTEAU-BETZER ,  Romain NAJMAN ,  Julien SANTO ,  Cécile APOLIT

IPC分类号： C07D215/38 ,  A61P31/14 ,  C07D401/12 ,  C07D405/12

摘要： A compound of formula (I) or any of its pharmaceutically acceptable salt for use in the treatment and/or prevention of a RNA virus infection, and a RNA virus infection from group IV or V of the Baltimore classification wherein R3 represents a chlorine atom or a hydrogen atom, R represents a (C1-C4)alkyl group, a (C3-C6)cycloalkyl group, a halogen atom, a (C1-C5)alkoxy group, a —SO2—NRaRb group, a —SO3H group, a —OH group, a —O—SO2—ORc group or a —O—P(═O)—(ORc)(ORd) group, R1 represents (i) a CF3 group, (ii) a (C1-C10)alkyl group, (iii) a (C3-C6)cycloalkyl or a (C3-C6)heterocycloalkyl group or (iv) a phenyl group or a naphthyl group, and R2 represents a hydrogen atom, a (C1-C10)alkyl group, a (C3-C6)cycloalkyl or a (C3-C6)heterocycloalkyl group and further relates to new compounds, to pharmaceutical compositions containing them and to synthesis process for manufacturing them.

公开(公告)号：US20210122732A1

公开(公告)日：2021-04-29

申请号：US17259451

申请日：2019-07-09

申请人： ABIVAX ,  CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE ,  UNIVERSITE DE MONTPELLIER ,  INSTITUT CURIE

发明人： Didier SCHERRER ,  Jamal TAZI ,  Florence MAHUTEAU-BETZER ,  Romain NAJMAN ,  Julien SANTO ,  Cécile APOLIT

IPC分类号： C07D401/12 ,  C07D405/12 ,  C07D413/12 ,  C07D205/04 ,  C07F7/18 ,  C07C237/40 ,  C07C255/50 ,  C07D213/81 ,  C07D213/74 ,  C07C311/16

摘要： A compound of formula (Ie): wherein Y1 represents an aryl group, X2 represents a —O— group, a —NH— group, a —S— group, a —CO—NH— group, a —NH—CO—NH— group, a —NH—CO— group, a —CH(OH)— group, a —CH(COOH)NH— group, a —CH(COOCH3)NH— group, a —C(OH)(CH2OH)—, a group, a divalent 5-membered heteroaromatic ring comprising 1, 2, 3 or heteroatoms, a —SO2— group, or a —SO2—NH— group, Y2 represents a hydrogen atom, a hydroxyl group, a (C1-C4)alkoxy group, a —CHC(OH)2, a COORf, wherein Rf represents a hydrogen atom or a (C1-C4)alkyl group, a morpholinyl group, a dihydropyranyl group, a group, a group, a —PO(ORf)(OR′f) group, wherein Rf and R′f independently represents a hydrogen atom or a (C1-C4)alkyl group, an oxetanyl group, a —Si(CH3)3 group, a —NHCOO—(C1-C4)alkyl group, or a —CR1R2R3 group, or any of its pharmaceutically acceptable salt and pharmaceutical compositions containing them and to synthesis process for manufacturing them.

公开(公告)号：US20160151348A1

公开(公告)日：2016-06-02

申请号：US14902935

申请日：2014-07-04

申请人： ABIVAX ,  CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE ,  INSTITUT CURIE ,  UNIVERSITE DE MONTPELLIER

发明人： Jamal TAZI ,  Florence MAHUTEAU-BETZER ,  Romain NAJMAN ,  Didier SCHERRER ,  Noëlie CAMPOS ,  Aude GARCEL

IPC分类号： A61K31/4709 ,  A61K31/497 ,  A61K31/498 ,  A61K31/47

CPC分类号： A61K31/4709 ,  A61K31/47 ,  A61K31/497 ,  A61K31/498 ,  A61K31/506

摘要： Methods for preventing or treating retroviral infection not HIV and/or for preventing, inhibiting or treating a disease caused by the retroviral infection include contacting a cell with compound (I) wherein: means a pyridazine, pyrimidine or pyrazine group, R independently represent a hydrogen atom, halogen atom or group chosen among a —CN, hydroxyl, —COOR1, (C1-C3)fluoroalkyl, (C1-C3)fluoroalkoxy, —NO2, —NR1R2, (C1-C4)alkoxy, phenoxy and (C1-C3)alkyl group, the alkyl being optionally mono-substituted by hydroxyl group, n is 1, 2 or 3, n′ is 1 or 2, R′ is a hydrogen atom, halogen atom or group chosen among (C1-C3)alkyl group, hydroxyl group, —COOR1 group, —NO2 group, —NR1R2 group, morpholinyl or morpholino group, N-methylpiperazinyl group, (C1-C3)fluoroalkyl group, (C1-C4)alkoxy group and —CN group, Z is N or C, Y is N or C, X is N or C, W is N or C, T is N or C, U is N or C.

摘要翻译： 用于预防或治疗逆转录病毒感染而不是HIV和/或用于预防，抑制或治疗由逆转录病毒感染引起的疾病的方法包括使细胞与化合物（I）接触，其中：表示哒嗪，嘧啶或吡嗪基，R独立地表示氢 原子，卤素原子或选自-CN，羟基，-COOR1，（C1-C3）氟烷基，（C1-C3）氟烷氧基，-NO2，-NR1R2，（C1-C4）烷氧基，苯氧基和（C1-C3） ）烷基，烷基任选被羟基单取代，n为1,2或3，n'为1或2，R'为氢原子，卤素原子或选自（C1-C3）烷基中的基团 ，羟基，-COOR1基，-NO2基，-NR1R2基，吗啉基或吗啉基，N-甲基哌嗪基，（C1-C3）氟烷基，（C1-C4）烷氧基和-CN基，Z是N或 C，Y为N或C，X为N或C，W为N或C，T为N或C，U为N或C。

公开(公告)号：US20150361491A1

公开(公告)日：2015-12-17

申请号：US14761674

申请日：2014-01-17

申请人： ABIVAX ,  CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE ,  UNIVERSITE DE MONTPELLIER

发明人： Jamal TAZI ,  Didier SCHERRER ,  Aude GARCEL ,  Noëlie CAMPOS ,  Romain NAJMAN ,  Florence MAHUTEAU-BETZER

IPC分类号： C12Q1/68 ,  C12Q1/70

CPC分类号： C12Q1/6876 ,  C12Q1/70 ,  C12Q2600/106 ,  C12Q2600/112 ,  C12Q2600/136 ,  C12Q2600/158 ,  C12Q2600/178

摘要： A use of at least one miRNA, said at least one miRNA being miR-124, as a biomarker, in particular of a viral infection, or of an efficacy of a therapeutic treatment of said viral infection.

摘要翻译： 使用至少一种miRNA，所述至少一种miRNA是miR-124，作为生物标志物，特别是病毒感染，或治疗性治疗所述病毒感染的功效。

公开(公告)号：US20160166519A1

公开(公告)日：2016-06-16

申请号：US14958602

申请日：2015-12-03

申请人： CENTRE NATIONALE DE RECHERCHE SCIENTIFIQUE ,  UNIVERSITE DE MONTPELLIER ,  INSTITUT CURIE

发明人： Jamal TAZI ,  David GRIERSON ,  Florence MAHUTEAU-BETZER ,  Pierre ROUX

IPC分类号： A61K31/166 ,  A61K31/4409 ,  A61K31/4725 ,  A61K31/4439 ,  A61K31/417 ,  A61K31/4406 ,  A61K31/4192

CPC分类号： A61K31/166 ,  A61K31/417 ,  A61K31/4192 ,  A61K31/4406 ,  A61K31/4409 ,  A61K31/4439 ,  A61K31/4725 ,  C07C237/30 ,  C07D213/38 ,  C07D213/56 ,  C07D213/74 ,  C07D213/75 ,  C07D213/82 ,  C07D233/61 ,  C07D233/64 ,  C07D249/06 ,  C07D401/12 ,  C07D401/14

摘要： A method of treating a disease selected from the group consisting of cancer, Duchenne muscular dystrophy, AIDS, and progeria, that includes administering to a patient in need thereof an effective quantity of at least one compound of formula (IV) or a pharmaceutically acceptable salt thereof.

摘要翻译： 一种治疗选自下组的疾病的方法，所述疾病包括癌症，杜氏肌营养不良症，艾滋病和原因，其包括向有需要的患者施用有效量的至少一种式（IV）化合物或其药学上可接受的盐 其中。